How Are Hot Flashes Connected to Cardiovascular Risk?

Hot Flashes Are a Vascular Event, Not Just a Sensation

A hot flash is a measurable cardiovascular event. It begins in the hypothalamus, where narrowed thermoneutral zones trigger sympathetic activation that dilates peripheral blood vessels, increases heart rate, and redirects blood flow to the skin 1. Skin temperature rises 1, 7°C within seconds. Heart rate increases by 7, 15 beats per minute. The entire episode reflects acute autonomic and vascular reactivity.

This distinction matters clinically. For decades, hot flashes were treated as a subjective quality-of-life complaint, separate from "real" cardiovascular pathology. That framing has shifted. A 2017 American Heart Association scientific statement acknowledged that adverse pregnancy outcomes and premature menopause are sex-specific risk factors for cardiovascular disease 2. Subsequent research has extended that recognition to the vasomotor symptoms themselves.

The physiologic cascade during a hot flash involves the same endothelial and autonomic pathways implicated in atherosclerosis. Repeated sympathetic surges, transient spikes in blood pressure, and cyclical changes in vascular tone create a pattern of hemodynamic stress. Dr. Rebecca Thurston, a professor of psychiatry, epidemiology, and psychology at the University of Pittsburgh, has described hot flashes as "a window into a woman's cardiovascular health rather than simply a reproductive symptom" 3.

The frequency matters too. A woman who has two hot flashes per week faces a different vascular load than one who has twelve per day. That dose-response pattern shows up consistently across imaging and outcomes data.

The SWAN Study Changed the Conversation

The Study of Women's Health Across the Nation (SWAN) is the largest longitudinal dataset linking vasomotor symptoms to subclinical cardiovascular disease. SWAN enrolled 3,302 women aged 42, 52 across seven U.S. sites and followed them through the menopausal transition for over two decades 4.

SWAN findings on VMS and cardiovascular markers include several key observations. Women reporting frequent VMS (6 or more days in the prior two weeks) had significantly greater carotid intima-media thickness (IMT), a validated surrogate for atherosclerotic burden, compared to women with no VMS. The association held after adjustment for age, BMI, smoking, lipids, blood pressure, and estradiol levels 5.

A critical nuance emerged around timing. Women whose VMS began early in the menopausal transition (perimenopause or early postmenopause) showed the strongest associations with aortic calcification and coronary artery calcium. Late-onset VMS, those appearing well after the final menstrual period, did not carry the same signal 6.

This timing pattern aligns with the "window hypothesis" of hormone therapy. The vascular system appears most responsive, and most vulnerable, during the years immediately surrounding the final menstrual period. Early-onset hot flashes may mark women whose vasculature is already showing signs of accelerated change.

SWAN also documented that women with persistent VMS (lasting more than 10 years) had worse cardiovascular risk profiles than those whose symptoms resolved within a few years. Persistence itself was a marker.

Endothelial Dysfunction: The Mechanistic Bridge

The endothelium, the single-cell layer lining every blood vessel, is where hot flashes and cardiovascular risk converge mechanistically. Healthy endothelium produces nitric oxide, maintains vascular tone, and resists plaque formation. Dysfunctional endothelium does none of these things well 7.

Estrogen is a direct modulator of endothelial nitric oxide synthase (eNOS). As estradiol levels decline during the menopausal transition, nitric oxide bioavailability drops. The result: stiffer arteries, impaired flow-mediated dilation (FMD), and a pro-inflammatory vascular environment 8.

Studies using brachial artery FMD testing during objectively monitored hot flashes show real-time endothelial impairment. In a 2010 study of 492 midlife women, those with physiologically monitored (not just self-reported) hot flashes had significantly lower FMD compared to asymptomatic women (5.8% vs. 7.1%, P=0.009), indicating worse endothelial function 9.

The inflammatory milieu compounds the problem. Hot flashes are associated with higher circulating levels of interleukin-6, C-reactive protein, and matrix metalloproteinase-9, all markers of vascular inflammation that predict cardiovascular events independently 10.

This is not a single-pathway story. The connection between hot flashes and cardiovascular risk runs through at least three overlapping mechanisms: autonomic dysregulation (repeated sympathetic surges), endothelial dysfunction (impaired nitric oxide signaling), and chronic low-grade inflammation. Each pathway has independent support in clinical data.

Coronary Artery Calcium and Imaging Evidence

Coronary artery calcium (CAC) scoring provides a direct, quantifiable measure of atherosclerotic plaque burden. Several studies have examined the relationship between VMS and CAC in midlife women.

In a cross-sectional analysis of 492 women from the MsHeart and MsBrain studies, women with frequent VMS had higher CAC scores (Agatston units) than those without symptoms, independent of traditional risk factors. The association was strongest among women in early menopause 11.

A 2021 analysis using SWAN-HDL (Heart and Diastolic Function) data found that women who reported VMS at baseline and were followed with serial cardiac imaging had greater progression of aortic calcification over 12 years compared to never-symptomatic women. The adjusted odds ratio for any aortic calcification was 1.39 (95% CI: 1.03, 1.89) among women with persistent VMS 12.

These imaging findings push the association beyond epidemiologic correlation. Calcium in coronary arteries is not a surrogate or a soft endpoint. It is plaque. And women with more severe or longer-lasting hot flashes carry more of it.

Carotid IMT data tell a parallel story. A meta-analysis of nine observational studies (N=10,037) found that women with VMS had 0.02 to 0.07 mm greater carotid IMT compared to asymptomatic women, an increment associated with approximately 10 to 15% higher stroke and myocardial infarction risk per standard deviation increase 13.

Cardiovascular Event Data: From Surrogates to Outcomes

Surrogate endpoints like IMT and CAC need confirmation from hard outcomes. That confirmation exists, though it is less uniform.

The Women's Health Initiative Observational Study followed 60,027 postmenopausal women for a median of 10 years. Women who reported moderate-to-severe VMS at enrollment had a higher rate of cardiovascular events (HR 1.23 to 95% CI 1.02, 1.49 for stroke) and a non-significant trend toward increased coronary heart disease 14. The signal was clearest in women who were normal weight and had early-onset symptoms.

A 2020 pooled analysis from European cohorts (N=19,946) found that women reporting severe VMS at baseline had a 51% higher risk of incident cardiovascular disease over 14 years (adjusted HR 1.51 to 95% CI 1.10, 2.08) compared to women with no or mild VMS 15.

Not all studies agree on magnitude. Some show attenuated associations after aggressive adjustment for BMI, hypertension, and lipids. This is expected. Hot flashes and traditional cardiovascular risk factors share upstream drivers, particularly estrogen withdrawal and sympathetic activation. Adjusting for downstream mediators can obscure real connections.

Dr. JoAnn Manson, professor of medicine at Harvard Medical School and principal investigator of the Women's Health Initiative hormone therapy trials, has stated: "Vasomotor symptoms should be viewed as a potential marker of cardiovascular vulnerability, particularly when they are severe, frequent, and occur early in the menopausal transition" 14.

Night Sweats May Carry Distinct Risk

Night sweats (nocturnal VMS) deserve separate consideration. Sleep disruption from night sweats raises cortisol, fragments sleep architecture, and activates the hypothalamic-pituitary-adrenal axis in patterns associated with insulin resistance and hypertension 16.

In the SWAN Sleep Study, women with objectively measured night sweats (via sternal skin conductance monitoring) had higher wake-after-sleep-onset (WASO) times and lower heart rate variability, a known predictor of cardiac events 17.

Sleep fragmentation independently raises cardiovascular risk. The combination of vascular reactivity from the hot flash itself plus chronic sleep disruption creates a compounding risk profile that neither factor alone explains. This is one reason why women who report "tolerable" daytime hot flashes but severe night sweats may still warrant treatment from a cardiovascular perspective.

What This Means for Hormone Therapy Decisions

The cardiovascular signal from hot flashes has direct implications for hormone therapy (HT) prescribing. The 2022 Menopause Society position statement affirms that for symptomatic women under 60 or within 10 years of menopause onset, the benefits of HT generally outweigh the risks 18.

Timing is the operative variable. The WHI randomized trials showed that conjugated equine estrogens (CEE) initiated in women aged 50, 59 were associated with a non-significant reduction in coronary heart disease (HR 0.76 to 95% CI 0.50, 1.16), while the same therapy initiated in women 70, 79 increased risk 19.

The ELITE trial (Early vs. Late Intervention Trial with Estradiol) provided mechanistic support. Women randomized to oral 17β-estradiol within 6 years of menopause had significantly slower progression of carotid IMT compared to placebo (difference in rate: -0.0044 mm/year, P=0.046). Women randomized more than 10 years after menopause showed no benefit 20.

For clinicians evaluating a woman with frequent, early-onset VMS, the data suggest a convergent rationale: treating symptoms and potentially modifying vascular trajectory with the same intervention. This does not mean HT is prescribed solely for cardioprotection. It does mean that cardiovascular risk context should inform the shared decision-making conversation rather than being treated as irrelevant to VMS management.

Non-hormonal options for VMS, including fezolinetant (a neurokinin 3 receptor antagonist approved by the FDA in 2023), reduce hot flash frequency and severity but lack cardiovascular outcome data. Whether symptom reduction alone improves vascular endpoints is an open question that current trials have not answered 21.

Screening Considerations for Symptomatic Women

Standard cardiovascular risk calculators (Pooled Cohort Equations, SCORE2) do not include VMS as an input variable. This is a gap. A woman with frequent early-onset hot flashes may score as "low risk" on standard calculators while carrying measurable subclinical disease.

The AHA's 2024 guidance on cardiovascular risk in women classifies premature menopause (before age 40) as a risk-enhancing factor that can shift management decisions, particularly statin eligibility 2. Severe VMS in the perimenopausal years should prompt similar consideration, even if formal guideline integration lags behind the evidence.

Clinicians managing symptomatic menopausal women should consider lipid panels, fasting glucose, blood pressure trending, and, where clinical suspicion warrants, CAC scoring. The cost of a CAC scan ($75, 150 out of pocket at most imaging centers) is low relative to the reclassification value it provides.

A woman who presents with daily hot flashes, poor sleep, and rising blood pressure is not presenting with three separate problems. She is presenting with one interconnected syndrome driven by estrogen withdrawal, autonomic instability, and vascular aging. Treating the symptom cluster together, rather than referring hot flashes to gynecology and blood pressure to internal medicine, produces better outcomes and avoids fragmented care.

Clinicians should ask every perimenopausal and postmenopausal woman about VMS frequency, severity, and duration at annual visits, and document the answers alongside traditional cardiovascular risk factors. A CAC score of zero in a 52-year-old with daily hot flashes is reassuring. A CAC score of 85 changes the conversation entirely.